Adaptive Biotechnologies (ADPT) Competitors

Adaptive Biotechnologies (NASDAQ:ADPT) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation.

Does the media favor ADPT or PCVX?

In the previous week, Vaxcyte had 10 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 16 mentions for Vaxcyte and 6 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.49 beat Vaxcyte's score of 1.26 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	10 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, ADPT or PCVX?

Adaptive Biotechnologies has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$178.96M	6.11	-$159.49M	-$1.09	-6.75
Vaxcyte	N/A	N/A	-$402.27M	-$3.80	-9.43

Do analysts recommend ADPT or PCVX?

Adaptive Biotechnologies currently has a consensus price target of $9.40, suggesting a potential upside of 27.72%. Vaxcyte has a consensus price target of $136.50, suggesting a potential upside of 280.86%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vaxcyte	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10

Which has more risk and volatility, ADPT or PCVX?

Adaptive Biotechnologies has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Does the MarketBeat Community believe in ADPT or PCVX?

Adaptive Biotechnologies received 43 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
Adaptive Biotechnologies	Outperform Votes 98 57.99%	Underperform Votes 71 42.01%
Vaxcyte	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%

Do institutionals & insiders have more ownership in ADPT or PCVX?

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 6.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is ADPT or PCVX more profitable?

Vaxcyte has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -89.12%. Vaxcyte's return on equity of -23.53% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-89.12%	-64.65%	-26.45%
Vaxcyte	N/A	-23.53%	-22.20%

Summary

Adaptive Biotechnologies and Vaxcyte tied by winning 9 of the 18 factors compared between the two stocks.